Short answer
Tyra Biosciences, Inc. (TYRA) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$51M
- −71.2% YoY · −12.2% QoQ
- EPS (diluted)
- −$0.74
- −48.0% YoY · −7.2% QoQ
Source: XBRL data from the Tyra Biosciences, Inc. (TYRA) Q3 2026 10-Q on SEC EDGAR. USD.
Tyra Biosciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, clinical-stage company with no product revenue
- Net loss $51.1M vs $29.9M YoY, operating margin not applicable with operating expenses $54.9M
- Dabogratinib IR NMIBC largest R&D program, $7.3M vs $1.8M YoY; TYRA-200 ICC lowest, $(0.1)M vs $0.0M
- Cash, equivalents and marketable securities $700.5M at September 30, 2026, financing proceeds $376.2M
- Runway through 2030; expected higher R&D spending, clinical-trial costs and operating losses, with tariffs and geopolitical risks as headwinds
Risk Factors
- No material changes to risk factors disclosed in the 2025 Annual Report
- Carried-forward risks include clinical-trial, regulatory approval, commercialization, and financing uncertainties
- Continued biotechnology competition and dependence on intellectual-property protection
- Ongoing need for additional capital to support operations and development programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tyra Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.